A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine
A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where
 administrations are given and any effects it may have on subjects' wellbeing. The study will
 also test the ability of vaccine to cause particular immune responses in the body.
Influenza is a contagious disease of the upper airways and the lungs. It rapidly spreads
 around the world in seasonal epidemics, killing hundreds of thousands of people and having
 high economic consequences due to healthcare costs and lost productivity. Each year
 governments recommend groups who are at risk of influenza or its complications to receive
 influenza vaccination. Current vaccine supply is not sufficient to meet the demand if this
 recommendation were to be taken up by all. This study is part of the clinical development of
 a particle mediated epidermal delivery (PMED) trivalent DNA vaccine for the prevention of
 influenza.This study will investigate the safety and tolerability of this vaccine as well as
 assess the humoral and cellular immunogenicity of the vaccine in healthy subjects.
Ages Eligible for Study:

 -  18 Years - 50 Years

 -  Genders Eligible for Study: Both

 -  Accepts Healthy Volunteers

 Criteria

 Inclusion Criteria:

 -  Healthy adult volunteers (women must be of non child-bearing potential)

 -  Provided written informed consent

 Exclusion Criteria:

 -  No significant concomitant illness

 -  No allergy to gold

 -  No immunosuppression due to disease or treatment

 -  No previous flu vaccination in 2005 or 2006